Article
Mesoporous bioactive glass in strontium-enhanced CPC increases new bone formation in an osteoporotic metaphyseal critical size defect in rats
Search Medline for
Authors
-
Ulrich Thormann
- Labor für Experimentelle Unfallchirurgie, Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany
-
Seemun Ray
- Justus-Liebig Universität, Labor für Experimentelle Unfallchirurgie, Gießen, Germany
-
Matthäus Budak
- Justus-Liebig Universität, Labor für Experimentelle Unfallchirurgie, Gießen, Germany
-
Matthias Schumacher
- Centre for Translational Bone, Joint and Soft Tissue, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
-
Michael Gelinsky
- Universitätsklinikum Dresden, Zentrum für Translationale Knochen-, Gelenk- und Weichgewebeforschung, Dresden, Germany
-
Marcus Rohnke
- Institut für Physikalische Chemie, Gießen, Germany
-
Christian Heiß
- Labor für Experimentelle Unfallchirurgie, Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Gießen und Marburg GmbH, Gießen, Gießen, Germany
-
Volker Alt
- Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Regensburg, Regensburg, Germany
| Published: | October 26, 2021 |
|---|
Outline
Text
Objectives: In this study the effect of mesoporous bioactive glass (MBG) particles incorporated in a pasty strontium-containing calcium phosphate bone cement (pS100G10) was studied in vivo in comparison to a plain pasty strontium-containing calcium phosphate bone cement (pS100) and control (empty defect) groups, respectively.
Methods: New bone formation was studied in a metaphyseal fracture-defect in ovariectomized rats.45 female Sprague-Dawley rats were randomly assigned to three different treatment groups: (1) pS100 (n=15), (2) pS100G10 (n=15), and (3) Empty defect (n=15). 12 weeks after bilateral ovariectomy and multi-deficient diet, a 4 mm wedge-shaped fracture-defect was created at the metaphyseal area of the left femur. It was filled with pS100, pS100G10 or left empty to serve as a control.
Results and Conclusion: After six weeks, histomorphometrical analysis revealed a statistically significant higher bone volume / tissue volume ratio in the pS100G10 group compared to pS100 (p=0.03) and empty defect (p=0.0001) indicating an improved osteoconductivity with the incorporation of MBG. These data could be attributed to the increase in the bone-morphogenic protein 2 expression. Also, immunohistochemistry revealed a significant decrease in the RANKL/OPG ratio for pS100 (p=0.004) and pS100G10 (p=0.003) compared to empty defect. In addition, a statistically significant higher gene expression of alkaline phosphatase, osteoprotegerin, collagen1a1, collagen10a1 with simultaneous decrease in RANKL and carbonic anhydrase was seen in pS100 and pS100G10 compared to empty defect. Mass spectrometric imaging by time of flight secondary ions mass spectrometry (ToF-SIMS) showed release of Sr2+ ions from both pS100 and pS100G10 with a gradient into the interface region. Furthermore, ToF-SIMS imaging revealed that resorption of the MBG particles allowed new bone formation in cement-pores. However, in vitro investigations showed no differences in the attachment or proliferation and viability of primary human osteoblasts for the MBG-incorporated cements. Together, the results suggest the injectable MBG/cement composite as a promising bone replacement material to treat critical size defects in osteopenic conditions.
